• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

一种转基因重链 IgG 小鼠平台,作为治疗应用的高亲和力全人源单域抗体的来源。

A Transgenic Heavy Chain IgG Mouse Platform as a Source of High Affinity Fully Human Single-Domain Antibodies for Therapeutic Applications.

机构信息

Cell Biology Department, Erasmus Medical Center, Rotterdam, The Netherlands.

Harbour BioMed, Rotterdam, The Netherlands.

出版信息

Methods Mol Biol. 2022;2446:121-141. doi: 10.1007/978-1-0716-2075-5_6.

DOI:10.1007/978-1-0716-2075-5_6
PMID:35157271
Abstract

The antibody repertoires of transgenic mice expressing human heavy chain only antibodies (HCAbs) can be retrieved from immune cells after antigen challenge. Compared with genetically modified rodents expressing conventional human antibodies (tetramers consisting of two heavy chains paired with two light chains), there is no chain pairing problem, since each antibody consists of a heavy chain dimer which is solely responsible for antigen binding. HCAbs can be obtained by classical hybridoma fusion, or the generation of phage libraries or eukaryotic cell libraries displaying or secreting HCAbs. Combined transcriptomic/serum proteomic approaches can also be used to determine the repertoire of antibodies, as well as single cell technologies such as the Beacon system that enable capture of immune cells of interest, analysis, and sequencing of antibodies in a short period of time. Here, we describe a protocol for obtaining monoclonal HCAbs from immunized Harbour transgenic mice through the generation and screening of HEK cell libraries of secreted antibodies. The method can be used routinely and is fast and affordable for everyone. Selected VH regions (single domains) are sequenced and individual HCAbs can be produced and purified from the same expression vector that is used for library generation (hIgG1 Fc). They can also be cloned into other expression plasmids and reformatted to equip them with a particular effector function, modify lifespan in serum, or optimize valency and avidity depending on the specific aim.

摘要

表达人重链抗体(HCAbs)的转基因小鼠的抗体库可以在抗原刺激后从免疫细胞中回收。与表达常规人抗体的基因修饰啮齿动物(由两条重链与两条轻链配对组成的四聚体)相比,不存在链配对问题,因为每个抗体由重链二聚体组成,重链二聚体仅负责抗原结合。HCAbs 可以通过经典的杂交瘤融合获得,也可以通过展示或分泌 HCAbs 的噬菌体文库或真核细胞文库的生成获得。结合转录组/血清蛋白质组学方法也可用于确定抗体库,以及单细胞技术,如 Beacon 系统,该系统可捕获感兴趣的免疫细胞,在短时间内分析和测序抗体。在这里,我们描述了一种从免疫 Harbour 转基因小鼠中获得单克隆 HCAbs 的方案,方法是生成和筛选分泌抗体的 HEK 细胞文库。该方法可以常规使用,对每个人来说都快速且经济实惠。选择 VH 区(单域)进行测序,可以从用于文库生成的相同表达载体(hIgG1 Fc)中生产和纯化单个 HCAbs。它们还可以被克隆到其他表达质粒中,并进行重新格式化,以赋予它们特定的效应功能,根据具体目标改变在血清中的半衰期,或优化效价和亲和力。

相似文献

1
A Transgenic Heavy Chain IgG Mouse Platform as a Source of High Affinity Fully Human Single-Domain Antibodies for Therapeutic Applications.一种转基因重链 IgG 小鼠平台,作为治疗应用的高亲和力全人源单域抗体的来源。
Methods Mol Biol. 2022;2446:121-141. doi: 10.1007/978-1-0716-2075-5_6.
2
Multispecific Antibody Development Platform Based on Human Heavy Chain Antibodies.基于人重链抗体的多特异性抗体开发平台。
Front Immunol. 2019 Jan 7;9:3037. doi: 10.3389/fimmu.2018.03037. eCollection 2018.
3
Llama peripheral B-cell populations producing conventional and heavy chain-only IgG subtypes are phenotypically indistinguishable but immunogenetically distinct.羊驼外周血 B 细胞中产生常规和重链仅有型 IgG 亚型的细胞表型无法区分,但免疫原性不同。
Immunogenetics. 2019 Apr;71(4):307-320. doi: 10.1007/s00251-018-01102-9. Epub 2019 Jan 18.
4
Nanobody-based CD38-specific heavy chain antibodies induce killing of multiple myeloma and other hematological malignancies.基于纳米抗体的 CD38 特异性重链抗体诱导杀伤多发性骨髓瘤和其他血液系统恶性肿瘤。
Theranostics. 2020 Feb 3;10(6):2645-2658. doi: 10.7150/thno.38533. eCollection 2020.
5
Expression Cloning and Production of Human Heavy-Chain-Only Antibodies from Murine Transgenic Plasma Cells.从小鼠转基因浆细胞中进行人源仅重链抗体的表达克隆与生产。
Front Immunol. 2016 Dec 19;7:619. doi: 10.3389/fimmu.2016.00619. eCollection 2016.
6
Genetic removal of the CH1 exon leads to the production of hypofunctional heavy chain-only IgG2a in rats.基因剔除 CH1 外显子导致大鼠产生功能低下的重链-only IgG2a。
Transgenic Res. 2020 Apr;29(2):199-213. doi: 10.1007/s11248-020-00189-9. Epub 2020 Feb 20.
7
CD38-Specific Biparatopic Heavy Chain Antibodies Display Potent Complement-Dependent Cytotoxicity Against Multiple Myeloma Cells.CD38 特异性双价重链抗体对多发性骨髓瘤细胞显示出强大的补体依赖性细胞毒性。
Front Immunol. 2018 Nov 19;9:2553. doi: 10.3389/fimmu.2018.02553. eCollection 2018.
8
Applications of High-Throughput DNA Sequencing to Single-Domain Antibody Discovery and Engineering.高通量 DNA 测序在单域抗体发现和工程中的应用。
Methods Mol Biol. 2023;2702:489-540. doi: 10.1007/978-1-0716-3381-6_26.
9
Novel Antibody Drug Conjugates Targeting Tumor-Associated Receptor Tyrosine Kinase ROR2 by Functional Screening of Fully Human Antibody Libraries Using Transpo-mAb Display on Progenitor B Cells.通过在祖细胞 B 细胞上使用 Transpo-mAb 展示对全人源抗体文库进行功能筛选,靶向肿瘤相关受体酪氨酸激酶 ROR2 的新型抗体药物偶联物。
Front Immunol. 2018 Nov 2;9:2490. doi: 10.3389/fimmu.2018.02490. eCollection 2018.
10
Comparative Analysis of Immune Repertoires between Bactrian Camel's Conventional and Heavy-Chain Antibodies.双峰驼常规抗体与重链抗体免疫组库的比较分析
PLoS One. 2016 Sep 2;11(9):e0161801. doi: 10.1371/journal.pone.0161801. eCollection 2016.

引用本文的文献

1
Generation of nanobodies from transgenic 'LamaMice' lacking an endogenous immunoglobulin repertoire.从缺乏内源性免疫球蛋白库的转基因“lamaMice”中产生纳米抗体。
Nat Commun. 2024 Jun 3;15(1):4728. doi: 10.1038/s41467-024-48735-x.
2
Next generation single-domain antibodies against respiratory zoonotic RNA viruses.针对呼吸道人畜共患RNA病毒的新一代单域抗体。
Front Mol Biosci. 2024 May 9;11:1389548. doi: 10.3389/fmolb.2024.1389548. eCollection 2024.
3
High throughput identification of human monoclonal antibodies and heavy-chain-only antibodies to treat snakebite.
用于治疗蛇咬伤的人单克隆抗体和仅重链抗体的高通量鉴定。
Toxicon X. 2024 Feb 16;21:100185. doi: 10.1016/j.toxcx.2024.100185. eCollection 2024 Mar.
4
Avidity engineering of human heavy-chain-only antibodies mitigates neutralization resistance of SARS-CoV-2 variants.重链抗体的高亲合力工程减轻了 SARS-CoV-2 变体的中和抗性。
Front Immunol. 2023 Feb 21;14:1111385. doi: 10.3389/fimmu.2023.1111385. eCollection 2023.
5
Assessing developability early in the discovery process for novel biologics.评估新型生物制剂发现过程中的可开发性。
MAbs. 2023 Jan-Dec;15(1):2171248. doi: 10.1080/19420862.2023.2171248.
6
An anti-CTLA-4 heavy chain-only antibody with enhanced T depletion shows excellent preclinical efficacy and safety profile.一种增强 T 细胞耗竭作用的抗 CTLA-4 重链仅有抗体具有优异的临床前疗效和安全性特征。
Proc Natl Acad Sci U S A. 2022 Aug 9;119(32):e2200879119. doi: 10.1073/pnas.2200879119. Epub 2022 Aug 4.